Paraneoplastic Autoimmune Neurological Syndromes and the Role of Immune Checkpoint Inhibitors.

ABSTRACT: The introduction of immune checkpoint inhibitors (ICIs) in oncologic therapies has led to a paradigm shift in cancer treatment. ICIs have increased the overall survival in patients with malignant melanoma, small-cell lung cancer, and many other tumor entities. Despite their clinical benefits, these novel cancer immunotherapies can induce neurological immune-related adverse events (irAEs). Such immune-mediated complications can manifest within the spectrum of paraneoplastic neurological syndromes (PNSs). PNSs are rare immune-mediated complications of systemic cancers that can involve every aspect of the nervous system. The emergence of PNSs with ICI treatment opens further pathways to study the complex immunopathological interplay of cancer immunity, cross-reactive neurological autoimmune p

SUBMITTER: Duong SL 

PROVIDER: S-EPMC9294109 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature